Inte onal Application No. PCT/US 97/18396

			LC1/02 3//10230
A. CLASS IPC 6	HFICATION OF SUBJECT MATTER C07C311/13		10 C07K5/062
According t	to International Patent Classification (IPC) or to both national classif	fication and IPC	
B. FIELDS	SEARCHED		
Minimum di IPC 6	ocumentation searched (classification system followed by classification CO7C CO7K CO7D	ation symbols)	
Oocumenta	ation searched other than minimum documentation to the extent that	such documents are include	d in the fields searched
Electronic d	data base consulted during the international search (name of data t	ease and, where practical, se	arch lerms used)
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category '	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.
Α	GB 2 292 149 A (FERRING RESEARCH 14 February 1996 see page 1 – page 5; claims 1,9	, ET AL.)	1,19
A	WO 95 05192 A (MERCK & CO.) 23 February 1995		1,19
Α	see page 4 - page 11; claims 1,1 A.M.M. MJALLI, ET AL.: "Activat as potent reversible inhibitors interleukin-1.beta. converting e BIOORGANIC AND MEDICINAL CHEMIST LETTERS, vol. 4, no. 16, 1994, OXFORD, GB pages 1965-1968, XP002053204 see the whole document	ed ketones of nzyme" RY	1,19
X Furth	er documents are listed in the continuation of box C.	X Patent family mem	bers are listed in annex.
"A" documer conside "E" earlier de filing de "L" documer which is citation "O" documer other m"P" documer later the	nt which may throw doubts on priority claim(s) or s cited to establish the publication date of another or other special reason (as specified) int referring to an oral disclosure, use, exhibition or neans nt published prior to the international filing date but an the priority date claimed	or prionty date and no cited to understand the invention "X" document of particular cannot be considered involve an inventive st "Y" document of particular cannot be considered document is combined.	ad after the international filling date t in conflict with the application but e principle or theory underlying the relevance; the claimed invention novel or cannot be considered to ep when the document is taken alone relevance; the claimed invention to involve an inventive step when the l with one or more other such docu- lon being obvious to a person skilled the same patent family
	octual completion of the International search January 1998	1	1 9. 02, 98
Name and m	tailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	Authorized officer	

3

Inti-ional Application No PCT/US 97/18396

		PCT/US 9	7/18396
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category '	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
	A.M.M. MJALLI, ET AL.: "Inhibition of interleukin-1.beta. converting enzyme by N-acyl-aspartic acid ketones" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 13, 1995, OXFORD, GB, pages 1405-1408, XP002053205 see the whole document		1,19
		,	

3

l' mational application No.

PCT/US 97/18396

Boxi	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This inte	rmational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim(s) 19-24, 26-31, 33-40, 48-57 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box ii	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Into	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remai	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Information on patent family members

Int :lonal Application No PCT/US 97/18396


Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2292149 A	14-02-96	NONE	
WO 9505192 A	23-02-95	AU 7714594 A	14-03-95

Form PCT/ISA/210 (patent lamily annex) (July 1992)

•)		

. ATENT COOPERATION TREATY

NOTED () FEB 2 4 1998



From the INTERNATIONAL SEARCHING AUTHORITY

To:
WARNER-LAMBERT COMPANY
Attn. RYAN, M. A.
201 Tabor Road
Morris Plains, New Jersey 07950
UNITED STATES OF AMERICA

ARMSTRUMECATION OF TRANSMITTATENT DEPT

(PCT Rule 44.1)

. OR THE DECLARATION

Date of mailing (day/month/year)

1 9. 02. 98

Applicant's or agent's file reference

5498-01-TMC

International application No. PCT/US 97/18396

International filing date

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International filing date (day/month/year)

09/10/1997

Applicant

WARNER-LAMBERT COMPANY et al.

1.	\mathbf{x}	The applic	cant is hereby n	otified that the International Search Report has been established and is transmitted herewith.
		Filing of	amendments a	ind statement under Article 19:
		The applic	cant is entitled,	if he so wishes, to amend the claims of the International Application (see Rule 46):
		When?	The time limit fo International Se	or filing such amendments is normally 2 months from the date of transmittal of the earch Report; however, for more details, see the notes on the accompanying sheet.
		Where?	Directly to the	International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41-22) 740.14.35
		For more	detailed instru	actions, see the notes on the accompanying sheet.
2.		The applic Article 17(cant is hereby n (2)(a) to that effi	otified that no International Search Report will be established and that the declaration under ect is transmitted herewith.
3.		With rega	ard to the prote	est against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
		the p	orotest together icants's request	with the decision thereon has been transmitted to the International Bureau together with the to forward the texts of both the protest and the decision thereon to the designated Offices.
		no d	ecision has bee	en made yet on the protest; the applicant will be notified as soon as a decision is made.
4.	Furt	her action((s): The appli	cant is reminded of the following:
	pric	ority claim,	must reach the	ne priority date, the international application will be published by the International Bureau. id or postpone publication, a notice of withdrawal of the international application, or of the International Bureau as provided in Rules 90 bis.1 and 90 bis.3, respectively, before the eparations for international publication.
	Withi wis	in 19 mont thes to post	hs from the pric tpone the entry	ority date, a demand for international preliminary examination must be filed if the applicant into the national phase until 30 months from the priority date (in some Offices even later)

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentiaan 2

NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 851 epo nl, Fax. (+31-70) 340-3016 Authorized officer

Maurizio Amodeo

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international policition. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been its filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged:
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- (Where originally there were 48 claims and after amendment of some claims there are 51):
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- (Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims):
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

it must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide

ATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification of	of Transmittal of International Search Report
5498-01-TMC	ACTION	220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 97/18396	09/10/1997	11/10/1996
Applicant		3,15,100
WARNED-I AMBERT COMPANY		
WARNER-LAMBERT COMPANY e	t al.	
This International Search Report has be according to Article 18. A copy is being	en prepared by this International Searching Aut transmitted to the International Bureau.	nority and is transmitted to the applicant
This International Search Report consis	ts of a total of <u>4</u> sheets. py of each prior art document cited in this report.	
1. X Certain claims were found u	nscerchable (see Box I).	
2. Unity of invention is lacking	(see Box II).	
The international application c international search was carried.	ontains disclosure of a nucleotide and/or amine of out on the basis of the sequence listing	o acid sequence listing and the
	ed with the international application.	
L) fu	mished by the applicant separately from the inter	The state of the s
	but not accompanied by a statement to the matter going beyond the disclosure in the	e effect that it did not include international application as filed.
Tr	anscribed by this Authority	
4. With regard to the title, X the	text is approved as submitted by the applicant.	• •
. <u>121</u>	text has been established by this Authority to re	sad as follows:
	,	
5. With regard to the abstract,		
	e text is approved as submitted by the applicant.	
	e text has been established, according to Rute 3 ox III. The applicant may, within one month from t earch Report, submit comments to this Authority.	the date of mailing of this International
6. The figure of the drawings to be pu	blished with the abstract is:	
C A1	suggested by the applicant.	None of the figures.
	cause the applicant failed to suggest a figure.	
<u> </u>	cause this figure better characterizes the inventi	on.

Form PCT/ISA/210 (first sheet) (July 1992)

remational application No.

INTERNATIONAL SEARCH REPORT

PCT/US 97/18396

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim(s) 19-24, 26-31, 33-40, 48-57 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is facking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

PCT/US 97/18396

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C311/13 C07C311/24

C07K5/072

C07D217/24

C07C311/06 A61K31/18

C07C311/10

C07K5/062

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07C C07K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *		Relevant to claim No.	
A	GB 2 292 149 A (FERRING RESEARCH, ET AL.) 14 February 1996 see page 1 - page 5; claims 1,9	1,19	
A	WO 95 05192 A (MERCK & CO.) 23 February 1995 see page 4 - page 11; claims 1,16	1,19	
A	A.M.M. MJALLI, ET AL.: "Activated ketones as potent reversible inhibitors of interleukin-1.beta. converting enzyme" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 16, 1994, OXFORD, GB, pages 1965-1968, XP002053204 see the whole document	1,19	
,	-/		
. !	·	- •	

Special categories of cited documents :	
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than, the priority date claimed	T" later document published after the international filing date or priority date and not in conflict with the application but called to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled "a" document member of the same patent family
Date of the actual completion of theinternational search	Date of mailing of the international search report
29 January 1998	1 9. 02. 98
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk	Authorized officer
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	English, R

Form PCT/ISA/216 (second sheet) (July 1992)

X Further documents are listed in the continuation of box C.

X Patent family members are listed in annex.

national Application No
PCT/US 97/18396

0.40		PCT/US 97/18396		
	alion) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.	
A	A.M.M. MJALLI, ET AL.: "Inhibition of interleukin-1.beta. converting enzyme by N-acyl-aspartic acid ketones" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 13, 1995, OXFORD, GB, pages 1405-1408, XP002053205 see the whole document		1,19	
			•	
	AT			
- 1				

page 2 of 2

Inicimation on patent family members

national Application No

	T	PC1/0	JS 97/18396
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2292149 A	14-02-96	NONE	
WO 9505192 A	23-02-95	AU 7714594 A	14-03-95

Form PCT/ISA/210 (patent family argent) (CEV 1992)

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY Mansmann, Ivo Warner-Lambert Company Patentwesen NOTIFICATION OF TRANSMITTAL OF Legal Division THE INTERNATIONAL PRELIMINARY c/o Godecke AG, Patents **EXAMINATION REPORT** -4. Nov. 1998 Mooswaldallee 1 Eing.: (PCT Rule 71.1) D-79090 Freiburg **ALLEMAGNE** Date of mailing (day/month/year) 03.11.98 Applicant's or agent's file reference IMPORTANT NOTIFICATION PD-5498-01-TMC International filing date (day/month/year) Priority date (day/month/year) International application No. 11/10/1996 PCT/US97/18396 09/10/1997 Applicant

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

WARNER-LAMBERT COMPANY et al.

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

UB

Name and mailing address of the IPEA

9)

European Patent Office D-80298 Munich Tel. (+49-89) 2399-0, Tx: 523656 epmu d Fax: (+49-89) 2399-4465 Authorized officer

Roche, S

Tel. (+49-89) 2399-8031







PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or	_	le reference	FOR FURTHER AC		See Notification of Transmittal of International Preliminary Examination Report (PCT/IPEA/416)		
PD-5498-0	1-TMC	· · · · · · · · · · · · · · · · · · ·					
International a	• •	n No.	International filing date (day/n	nonth/year)	Priority date (day/month/year)		
PCT/US97	/18396		09/10/1997		11/10/1996		
		assification (IPC) or n	ational classification and IPC				
C07C311/	13						
Applicant							
WARNER-	LAMBE	RT COMPANY 6	t al.				
			nination report has been pre according to Article 36.	pared by this	s International Preliminary Examining Authority		
2. This RE	EPORT (consists of a total o	f 5 sheets, including this co	over sheet.			
□ Th	is repor	r is also accompan	ied by ANNEXES: i.e., shee	ts of the des	cription, claims and/or drawings		
wh	nich hav	e been amended a	nd are the basis for this repo	ort and/or sh	eets containing rectifications made rative Instructions under the PCT).		
		, , , , , , , , , , , , , , , , , , , ,			,		
These	annexes	consist of a total of	of sheets.				
3. This re	port con	tains indications re	lating to the following items:		. .		
1	⊠ E	Basis of the report					
		Priority	•				
111		-	of opinion with regard to nov	elty, inventiv	ve step and industrial applicability		
IV							
V			nt under Article 35(2) with re nations supporting such state		Ity, inventive step or industrial applicability;		
VI		Certain documents					
VII	⊠ (Certain defects in t	ne international application		•		
VIII	⊠ (Certain observation	s on the international applic	ation			
Date of sub	mission o	f the demand		Date of comple	ation of this report		
30/04/19	98		1	0 3. 11. 98			
Name and	mailing ac	dress of the IPEA/		Authorized officer			
ĺ		<u>.</u>			September 12 Marketon		
		ean Patent Office 98 Munich		(leidemigg,			

Telephone No. (+49-89) 2399-2143

Fax: (+49-89) 2399-4465

Tel. (+49-89) 2399-0, Tx: 523656 epmu d





INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US97/18396

1.	Basis	of	the	re	port

1.	resp	This report has been drawn on the basis of (substitute sheets which have been fumished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.):								
	Des	Description, pages:								
	1-36	3	as originally filed							
	Clai	ms, No.:								
	1-58		as originally filed							
2.	The	amendments have	e resulted in the cancellation of:							
		the description,	pages:							
		the claims,	Nos.:							
		the drawings,	sheets:							
3.			een established as if (some of) the amendments had not been made, since they have been beyond the disclosure as filed (Rule 70.2(c)):							
4.	Ado	litional observation	s, if necessary:							
111	. Noi	n-establishment o	of opinion with regard to novelty, inventive step and industrial applicability							
			ne claimed invention appears to be novel, to involve an inventive step (to be non-obvious), cable have not been examined in respect of:							
		the entire internal	cional application.							
	×	claims Nos. 19-24	4, 26-31, 33-40, 48-57.							
b	ecaus	se:								
	×		onal application, or the said claims Nos. 19-24, 26-31, 33-40, 48-57 relate to the following							





INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

International application No. PCT/US97/18396

see :	sep	arate	sheet
-------	-----	-------	-------

- ☐ the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify): ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- 1. Statement

Novelty (N)

Yes:

Claims 3, 4, 7, 9-18, 32, 41-47, 58

No:

Claims 1, 2, 5, 6, 8, 25

Inventive step (IS)

Yes: Claims

No:

Claims 1-18, 25, 32, 41-47, 58

Industrial applicability (IA)

Yes:

Claims 1-18, 25, 32, 41-47, 58

No:

no international search report has been established for the said claims Nos. .

Claims 19-24, 26-31, 33-40, 48-57

2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

s e separate sh et



Section III

Claims 19-24, 26-31, 33-40 and 48-57 relate to a method for the treatment of the human body (Rule 67.1 iv PCT).

EXAMINATION REPORT - SEPARATE SHEET

For the assessment of the present claims 19-24, 26-31, 33-40 and 48-57 on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Section V

Novelty

Claim 1 of the present application is not novel in the sense of Article 33(2) PCT. Document WO 95 05192 (D1), which is considered to represent the closest prior art discloses a compound of the general formula I (cf. p. 4, lines 14-18) with $R_1 = C_{1-6}$ alkyl; $R_2 = -SO_2$ -Ph; $R_3 =$ hydrogen, X_1 , X_2 , $X_3 =$ amino acid; Y = NH-, which is falling under the scope of the subject matter of claim 1. In claim 1 of the present application compounds of the general formula I with $R^1 = R^3 - CO - (A)_m$ - with $R^3 = C_1 - C_6$ alkyl, A = amino acid, M = 3; $R^2 = -(CH_2)_n - Z$ with Z = Aryl (not delimiting from phenyl), N = 0 are disclosed. In this case an overlap between the two general formulae of D1 and the present application is existing. Therefore, the applicant has to remove this overlap in order to establish novelty. The directly or indirectly dependent claims 2, 5, 6, 8 and 25 do not contain any features, which could establish novelty.

Inventive Step

Even if the applicant is able to establish novelty, the present application would not be inventive (Article 33(3) PCT), because the technical teaching of D1 proposes compounds, which show interleukin-1ß converting enzyme inhibiting activity. Since the compounds of D1 and the present application are structurally so closely related, it is obvious for a person skilled in the art, that the compounds of the present application will





INTERNATIONAL PRELIMINARY

International application No.

PCT/US97/18396

EXAMINATION REPORT - SEPARATE SHEET

also inhibit the interleukin-1ß converting enzyme.

Section VII

Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document WO 95 05192 is not mentioned in the description, nor is this document identified therein.

Section VIII

The term "cycloalkyl" in claims 1 and 11 is unclear, because no chainlenght is indicated. Therefore, the definition given on page 11, lines 19-23 should be incorporated within claims 1 and 11.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT AU	Armenia Austria	FI	Finland					
AU	Accetula		Littatio	LT	Lithuania	SK	Slovakia	
	Austria	FR	France	LU	Luxembourg	SN	Senegal	
	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland	
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad	
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo	
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan	
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan	
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey	
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago	
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine	
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda	
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America	
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan	
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam	
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia	
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe	
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand			
CM	Cameroon		Republic of Korea	PL	Poland			
CN	China	KR	Republic of Korea	PT	Portugal			
cu	Cuba	KZ	Kazakstan	RO	Romania			
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation	•		
DE	Germany	LI	Liechtenstein	SD	Sudan			
DK	Denmark	LK	Sri Lanka	SE	Sweden			
EE	Estonia	LR	Liberia	SG	Singapore			